Clinical trial · Observational
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)
An Observational Study of Avastin® (Bevacizumab) in Combination With Chemotherapy for Treatment of First-line Metastatic Colorectal Adenocarcinoma
NCT01506167CI-TRIAL-00032895completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This prospective, multi-center, observational study will assess the safety and efficacy of Avastin (bevacizumab) in daily practice in patients with metastatic colorectal cancer who have received no previous treatment for advanced disease and are receiving Avastin in combination with a standard of care first-line chemotherapy regimen. Data will be collected for 1.5 years or until death.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bevacizumab | Drug | Bevacizumab | ALIAS |
| Capecitabine | Drug | Capecitabine | ALIAS |
| Capecitabine/Oxaliplatin | Drug | CAPOX Regimen | ALIAS |
| Fluorouracil +/- Folinic Acid | Drug | — | UNRESOLVED |
| Fluorouracil/Folinic Acid/Irinotecan | Drug | FOLFIRI Regimen | ALIAS |
| Fluorouracil/Folinic Acid/Oxaliplatin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (7)
- label
- Bevacizumab and Capecitabine/Oxaliplatin
- description
- Participants who receive bevacizumab in combination with capecitabine/oxaliplatin
- interventionNames
- Drug: Bevacizumab
- Drug: Capecitabine/Oxaliplatin
- label
- Bevacizumab and Fluorouracil/Folinic Acid/Oxaliplatin
- description
- Participants who receive bevacizumab in combination with fluorouracil/folinic acid/oxaliplatin
- interventionNames
- Drug: Bevacizumab
- Drug: Fluorouracil/Folinic Acid/Oxaliplatin
- label
- Bevacizumab and Capecitabine
- description
- Participants who receive bevacizumab in combination with capecitabine
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Metastatic colorectal cancer with no previous systemic treatment for advanced disease * Receiving Avastin in combination with a first-line standard of care chemotherapy regimen * Avastin initiated at the same time as first-line chemotherapy regimen Exclusion Criteria: * Investigational, non-standard of care first-line chemotherapy regimen for treatment of metastatic colorectal cancer * Contraindication to Avastin
References
Publications (1)
- DERIVEDKhakoo S, Chau I, Pedley I, Ellis R, Steward W, Harrison M, Baijal S, Tahir S, Ross P, Raouf S, Ograbek A, Cunningham D; ACORN investigators. ACORN: Observational Study of Bevacizumab in Combination With First-Line Chemotherapy for Treatment of Metastatic Colorectal Cancer in the UK. Clin Colorectal Cancer. 2019 Dec;18(4):280-291.e5. doi: 10.1016/j.clcc.2019.07.003. Epub 2019 Jul 11. PMID 31451367